智翔金泰2025年度归母净亏损5.36亿元

Core Viewpoint - Zhixiang Jintai (688443.SH) reported a significant increase in total operating revenue for the year 2025, while narrowing its net loss, indicating positive developments in its commercial product sales and licensing agreements [1] Group 1: Financial Performance - The company achieved total operating revenue of 231 million, representing a year-on-year increase of 666.65% [1] - The operating loss narrowed by 33.57% compared to the previous year [1] - The total profit loss decreased by 32.74% year-on-year [1] - The net profit attributable to the parent company owners showed a reduction in loss by 32.74% compared to the same period last year [1] Group 2: Product and Market Development - The growth in revenue is primarily attributed to the expansion of the sales market for its first commercial product, Saliqi monoclonal antibody injection (Jinlixi) [1] - The licensing income from the GR1803 injection's authorization and commercialization agreement had a significant positive impact on the company's net profit for the period [1]